Kimball Electronics Inc

Aktienanalyse zu Kimball Electronics Inc (KE)

$25.860

-1.102 (-4.26%)Zum Schluss

Loading chart…
Hoch
26.520
Eröffnung
26.180
Volumengewichteter Durchschnittskurs
25.97
Volumen
115.52K
Marktkap.
542.89M
Tief
25.540
Umsatz
3.00M
EV/EBITDA, TTM
6.50

Kimball Electronics, Inc. is a global, multifaceted manufacturer offering electronics manufacturing services (EMS) and contract manufacturing organization (CMO) solutions. It provides electronics manufacturing services, including engineering and supply chain support, to customers in the automotive, medical, and industrial end markets. Its CMO solutions include operations such as precision molded plastics and cold chain management to drug integration. The Company provides contract manufacturing services, including engineering and supply chain support, for the production of electronic assemblies and other products including medical devices, medical disposables, precision molded plastics, and complete device assembly primarily in automotive, medical, and industrial applications. The Company has acquired a Contract Development and Manufacturing Organization (CDMO), based in Europe and with operations in India focused on microfluidics, diagnostics, and drug delivery.

KI-Analyse of Kimball Electronics Inc (KE)

Halten

Kimball Electronics is currently not a strong buy due to its recent performance and technical indicators, despite potential growth in the medical segment. The current price is $24.60, with an RSI of 20.648 indicating oversold conditions, but the forward P/E ratio of 23.2019 suggests high valuation risks. The main risk is the 14.55% year-to-date decline, which raises concerns about market demand and revenue stability.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Kimball Electronics Inc (KE) beträgt 23.09, verglichen mit dem 5-Jahres-Durchschnitt von 15.17.

Erwartetes KGV

Überbewertet
5J-Durchschnitt P/E
15.17
Aktuelles P/E
23.09
Überbewertet
20.59
Unterbewertet
9.74

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
7.28
Aktuelles EV/EBITDA
6.50
Überbewertet
9.22
Unterbewertet
5.33

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
0.35
Aktuelles P/S
0.40
Überbewertet
0.42
Unterbewertet
0.28

Alphio-AI-Kursszenarien für KE

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%KE

$15.19

Szenariopreis

B

Basis

Basis · 50%KE

$13.74

Szenariopreis

B

Bärisch

Bärisch · 25%KE

$11.09

Szenariopreis

Event-Zeitleiste

2026-08-12 (ET)

16:30:00

Sees FY27 CapEx at $50M-$60M

16:30:00

Company Reports Q4 Revenue of $371.6M, Below Expectations

2026-07-01 (ET)

06:00:00

Kimball Electronics Acquires Helvoet Polymer Technologies for €90M

2026-05-05 (ET)

16:10:00

Company Confirms FY26 CapEx View of $50M-$60M

16:10:00

Company Reports Q3 Revenue of $352.9M, Below Expectations

News

KE FAQ – beantwortet von Alphio AI

Kimball Electronics, Inc. is a global, multifaceted manufacturer offering electronics manufacturing services (EMS) and contract manufacturing organization (CMO) solutions. It provides electronics manufacturing services, including engineering and supply chain support, to customers in the automotive, medical, and industrial end markets. Its CMO solutions include operations such as precision molded plastics and cold chain management to drug integration. The Company provides contract manufacturing services, including engineering and supply chain support, for the production of electronic assemblies and other products including medical devices, medical disposables, precision molded plastics, and complete device assembly primarily in automotive, medical, and industrial applications. The Company has acquired a Contract Development and Manufacturing Organization (CDMO), based in Europe and with operations in India focused on microfluidics, diagnostics, and drug delivery. It operates in the Technology sector (PRINTED CIRCUIT BOARDS industry).

Kimball Electronics is currently not a strong buy due to its recent performance and technical indicators, despite potential growth in the medical segment. The current price is $24.60, with an RSI of 20.648 indicating oversold conditions, but the forward P/E ratio of 23.2019 suggests high valuation risks. The main risk is the 14.55% year-to-date decline, which raises concerns about market demand and revenue stability.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln